Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607993 | 0.88 | TRPV1 (0.41) | SGMS2ROCK2VNN1 | |
| SCHEMBL1997464 | 0.88 | TDP1 (0.40) | POLBPDE4B | |
| SCHEMBL1994497 | 0.87 | MMP1 (0.41) | ROCK2GSK3BADORA1 | |
| SCHEMBL1996996 | 0.85 | SGMS2 (0.38) | SGMS2ROCK2POLBRXFP1BTK | |
| SCHEMBL1999844 | 0.85 | MMP1 (0.41) | — | |
| SCHEMBL1994786 | 0.83 | PDE4A (0.40) | PDE4B | |
| SCHEMBL2002231 | 0.83 | KMT2A (0.42) | POLBGSK3BPDE4B | |
| SCHEMBL1994456 | 0.81 | KDM4C (0.36) | POLBPDE4B | |
| SCHEMBL2828114 | 0.80 | ROCK2 (0.39) | SGMS2ROCK2POLBRXFP1 | |
| SCHEMBL1998502 | 0.80 | MAPT (0.39) | SGMS2ADORA1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960383-B2 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL SA (ES) | 2011-06-14 | — | — | US | claimed |
| EP-1758869-B1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALMIRALL SA (ES) | 2010-12-22 | — | — | EP | claimed |
| US-20080280918-A1 | Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors | ALMIRALL PRODESFARMA, SA (ES) | 2008-11-13 | — | — | US | claimed |
| US-7960383-B2 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL SA (ES) | 2011-06-14 | — | — | US | disclosed |
| EP-1758869-B1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALMIRALL SA (ES) | 2010-12-22 | — | — | EP | disclosed |
| US-20080280918-A1 | Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors | ALMIRALL PRODESFARMA, SA (ES) | 2008-11-13 | — | — | US | disclosed |
| EP-1758869-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123692-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280918-A1 | Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors | PDE12, PDE4A, PDE4B | SGMS2 4260/4885ROCK2 95/4885POLB 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.